Clinical Trials Logo

Vascular Diseases clinical trials

View clinical trials related to Vascular Diseases.

Filter by:

NCT ID: NCT00217919 Completed - Clinical trials for Cardiovascular Diseases

Reducing Risk Factors in Peripheral Arterial Disease

Start date: February 2006
Phase: N/A
Study type: Interventional

The purpose of this study is to compare a health-counselor mediated telephone counseling intervention to usual care to reduce low density lipoprotein cholesterol (LDL-C) levels in patients with peripheral arterial disease (PAD).

NCT ID: NCT00214825 Completed - Diabetes Mellitus Clinical Trials

Aldosterone and Vascular Disease in Diabetes Mellitus

Start date: August 2003
Phase: N/A
Study type: Interventional

Specific aims for this proposal are to determine in patients with diabetes mellitus the effects of an aldosterone receptor antagonist on: 1. Coronary microvascular function assessed by MRI perfusion reserve, 2. Endothelial dysfunction assessed by brachial artery reactivity studies, and 3. Inflammation assessed by blood measurements of c-reactive protein (CRP), monocyte chemoattractant protein-1 (MCP-1), and plasminogen activator inhibitor-1 (PAI-1).

NCT ID: NCT00205790 Completed - Clinical trials for Peripheral Vascular Diseases

GORE-TEX PROPATEN Vascular Graft Study

Start date: February 2003
Phase: N/A
Study type: Interventional

To demonstrate equivalence in patency performance of GORE-TEX PROPATEN Vascular Grafts and Thin Walled GORE-TEX Stretch Vascular Grafts in a peripheral bypass application to support a claim of substantial equivalence.

NCT ID: NCT00189540 Completed - Clinical trials for Peripheral Vascular Disease

Study of Hepatocyte Growth Factor (HGF) Via Plasmid Vector to Improve Perfusion in Critical Limb Ischemia Patients With Peripheral Ischemic Ulcers

Start date: August 2005
Phase: Phase 2
Study type: Interventional

The objective of this study is to test the hypothesis that AMG0001 treatment is safe and induces angiogenesis as detected by improved wound healing, reduction in amputation, improved pain at rest and hemodynamic measurement and to assess the effectiveness of the administrative method.

NCT ID: NCT00185276 Completed - Clinical trials for Peripheral Vascular Disease

Magnevist® Injection Enhanced MRA at Two Dose Levels Compared to Non Contrast MRA for the Detection of Structural Abnormalities of the Infrarenal Aorta and Peripheral Arteries

Start date: March 2003
Phase: Phase 3
Study type: Interventional

The purpose of this study is to look at the safety (what are the side effects) and efficacy (how well does it work) of Magnevist (the study drug) used for MRI of the infrarenal aorta and peripheral arteries. The results will be compared to the results of MRI taken without Magnevist, and with the results of your X-ray angiography.

NCT ID: NCT00180505 Completed - Clinical trials for Peripheral Vascular Diseases

ASSESS Study: Evaluation of ABSOLUTE™ Stent System for Occluded Arteries

Start date: March 2005
Phase: Phase 4
Study type: Interventional

The purpose of this study is to investigate the performance of the ABSOLUTE™ .035 peripheral self-expanding stent system in preventing restenosis of occluded or stenotic superficial femoral or proximal popliteal arteries.

NCT ID: NCT00180479 Completed - Clinical trials for Coronary Artery Disease

SPIRIT III Clinical Trial of the XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)

Start date: June 2005
Phase: Phase 3
Study type: Interventional

This study is divided into 5 arms: 1. Randomized Clinical Trial (RCT): Prospective, randomized, active-controlled, single blind, parallel two-arm multi-center clinical trial in the United States (US) comparing XIENCE V® Everolimus Eluting Coronary Stent System (CSS) (2.5, 3.0, 3.5 mm diameter stents) to the Food and Drug Administration (FDA) approved commercially available active control TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent (TAXUS® EXPRESS2™ PECS) System 2. US 2.25 mm non-randomized arm using 2.25 mm diameter XIENCE V® Everolimus Eluting CSS 3. US 4.0 mm non-randomized arm using 4.0 mm diameter XIENCE V® Everolimus Eluting CSS 4. US 38 mm non-randomized arm using 38 mm in length XIENCE V® Everolimus Eluting CSS 5. Japanese non-randomized arm using XIENCE V® Everolimus Eluting CSS (2.5, 3.0, 3.5, 4.0 mm diameter stents) in Japan The TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent System is Manufactured by Boston Scientific.

NCT ID: NCT00180453 Completed - Clinical trials for Coronary Artery Disease

SPIRIT FIRST Clinical Trial of the Abbott Vascular XIENCE V® Everolimus Eluting Coronary Stent System

Start date: December 2003
Phase: Phase 3
Study type: Interventional

Prospective, randomized, controlled, single-blinded, parallel two-arm, multicenter trial. Test arm: XIENCE V® Everolimus Eluting Coronary Stent System(stent length: 18mm, diameter: 3.0mm) Control arm: Metallic stent (MULTI-LINK VISION® metallic stent(stent length: 18mm, diameter: 3.0mm) Follow-up angiographic imaging and intra vascular ultra sound (IVUS) at 180 days and 1 year

NCT ID: NCT00163267 Completed - Clinical trials for Peripheral Vascular Diseases

Mirror Trial - Follow-Up Management of Peripheral Arterial Intervention With Clopidogrel

Start date: September 2005
Phase: Phase 2/Phase 3
Study type: Interventional

The Mirror Study is a randomized, double-blinded mono-centre trial the access the periinterventinal and postinterventional administration of clopidogrel in patients with peripheral vascular disease.

NCT ID: NCT00154141 Completed - Clinical trials for Peripheral Vascular Disease

Evaluation of Fibrin Sealant 2 in Vascular Surgical Procedures

Start date: June 2005
Phase: Phase 3
Study type: Interventional

A comparison of a fibrin sealant versus manual compression in stopping surgical bleeding during vascular procedures.